The price of Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $0.81 in the last session, down -6.26% from day before closing price of $0.86. On the day, 538121 shares were traded.
Ratios:
We take a closer look at CDTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.41.
On September 22, 2021, WBB Securities Upgraded its rating to Strong Buy which previously was Buy but kept the price unchanged to $6.25.
On March 04, 2021, Aegis Capital started tracking the stock assigning a Buy rating and target price of $9.Aegis Capital initiated its Buy rating on March 04, 2021, with a $9 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 ’24 when Tari Leslie sold 21,029 shares for $0.67 per share. The transaction valued at 14,085 led to the insider holds 258,681 shares of the business.
Sandison Taylor sold 20,662 shares of CDTX for $13,839 on Mar 11 ’24. The Chief Medical Officer now owns 347,095 shares after completing the transaction at $0.67 per share. On Mar 11 ’24, another insider, Ward Shane, who serves as the COO & CLO of the company, sold 20,473 shares for $0.67 each. As a result, the insider received 13,713 and left with 198,770 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.30 while its Price-to-Book (P/B) ratio in mrq is 9.11.
Stock Price History:
Over the past 52 weeks, CDTX has reached a high of $1.48, while it has fallen to a 52-week low of $0.59.
Shares Statistics:
A total of 90.62M shares are outstanding, with a floating share count of 81.59M. Insiders hold about 9.96% of the company’s shares, while institutions hold 29.71% stake in the company.
Earnings Estimates
The company has Fidelity Disruptive Technology analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $5.24, with high estimates of $1.47 and low estimates of $0.81.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
